AMPH Stock: Price, Earnings History and SEC Filings
Amphastar Pharmaceuticals, Inc. (AMPH) last traded at $27.72, up 2.93% on the latest session and up 7.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.80 against an analyst estimate of $0.51, a beat of 56.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
AMPH earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $0.80 | $0.51 | +56.86% |
| Mar 2026 | May 7, 2026 | $0.26 | $0.62 | -58.06% |
| Dec 2025 | Feb 26, 2026 | $0.61 | $0.89 | -31.46% |
| Sep 2025 | Nov 6, 2025 | $0.83 | $0.73 | +13.70% |
AMPH beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How AMPH reacts to earnings
Across its last 8 earnings releases, AMPH moved 10.6% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +4.90% |
| 2026-05-07 | After close | -20.93% |
| 2026-02-26 | After close | -23.63% |
| 2025-11-06 | After close | -0.83% |
| 2025-08-07 | After close | +10.13% |
| 2025-05-07 | After close | +0.90% |
| 2025-02-27 | After close | -9.72% |
| 2024-11-06 | After close | -13.69% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
AMPH financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $720M | $98M | $121M | 13.6% | $2.03 |
| 2024 | $732M | $160M | $172M | 21.8% | $3.06 |
| 2023 | $644M | $138M | $145M | 21.3% | $2.60 |
| 2022 | $499M | $91M | $65M | 18.3% | $1.74 |
| 2021 | $438M | $62M | $71M | 14.2% | $1.25 |
| 2020 | $350M | $1M | $23M | 0.4% | $0.03 |
| 2019 | $322M | $49M | $207000 | 15.2% | $0.98 |
| 2018 | $295M | -$6M | -$9M | -1.9% | $-0.12 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for AMPH
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 13, 2026Officer or director change
- 8-K · Jul 8, 2026Other events
- 8-K · Jun 3, 2026Shareholder vote
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 13, 2026
- 8-K · Mar 16, 2026Other events
- 8-K · Mar 6, 2026Officer or director change, Financial statements and exhibits
Insider filing activity
AMPH insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
AMPH news
- 3 profitable stocks with warning signsOct 30, 2026 · finance.yahoo.com
- BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out forOct 29, 2026 · finance.yahoo.com
- Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026Oct 29, 2026 · finance.yahoo.com
- 3 value stocks that fall shortOct 29, 2026 · finance.yahoo.com
- Bausch Health (BHC) Surpasses Q3 Earnings and Revenue EstimatesOct 28, 2026 · finance.yahoo.com
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. (AMPH) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.